Key Points Forecasts call for Teva's branded drug portfolio to bring it $3.7 billion in revenue next year. At the same time, as it pivots toward high-margin drug products, Teva continues to reduce debt and improve its credit rating. With management guiding toward a branded pivot that could eventually generate over $10 billion annually, there may be far more runway for Teva's turnaround rally. 10 stocks we like better than Teva Pharmaceutical Industries › Teva Pharmaceuticals (NYSE: TEVA) recently hit a new 52-week high of $40.79 per share and has surged 110% in the last year. It's the drugmaker's turnaround, fueled by a pivot from generic to branded products, driving this mega rally among pharmaceutical stocks .
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.